Research
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study
BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2459 (Published 10 June 2010) Cite this as: BMJ 2010;340:c2459
Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Appendix: Subgroup analysis by treatment arm
Related articles
- Editorial Published: 10 June 2010; BMJ 340 doi:10.1136/bmj.c2834
- Paper Published: 08 January 1994; BMJ 308 doi:10.1136/bmj.308.6921.81
- Analysis Published: 01 May 2012; BMJ 344 doi:10.1136/bmj.e2941
- Research Published: 04 July 2012; BMJ 345 doi:10.1136/bmj.e4203
See more
- The BMJ Christmas appeal 2016-7: Orbis, the sight saversBMJ December 01, 2016, 355 i6425; DOI: https://doi.org/10.1136/bmj.i6425
- Leaps in the darkBMJ December 01, 2016, 355 i6447; DOI: https://doi.org/10.1136/bmj.i6447
- NHS spent 8% more on medicines last yearBMJ November 23, 2016, 355 i6320; DOI: https://doi.org/10.1136/bmj.i6320
- Seven days in medicine: 9 to 15 November 2016BMJ November 17, 2016, 355 i6106; DOI: https://doi.org/10.1136/bmj.i6106
- Babies with microcephaly in Brazil are struggling to access careBMJ November 16, 2016, 355 i6157; DOI: https://doi.org/10.1136/bmj.i6157
Cited by...
- Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease
- Contextualising Single-Arm Ophthalmology Trials With Real-World Data: An Emulated Target Trial Comparing The Efficacy of Interventions For Neovascular Age-Related Macular Degeneration
- TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands
- Repeatability of swept-source optical coherence tomography retinal and choroidal thickness measurements in neovascular age-related macular degeneration
- UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections
- Ophthalmic statistics note 7: multiple hypothesis testing--to adjust or not to adjust
- Suppression of Choroidal Neovascularization Through Inhibition of APE1/Ref-1 Redox Activity
- Ophthalmic statistics note 2: absence of evidence is not evidence of absence
- Odds and odds ratios
- Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
- Implications of "not me" drugs for health systems: lessons from age related macular degeneration
- Assessment of Differential Pharmacodynamic Effects Using Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration
- Trends over time and geographical variation in rates of intravitreal injections in England
- Natural History of Age-Related Retinal Lesions That Precede AMD in Mice Fed High or Low Glycemic Index Diets
- Treatments for macular degeneration: summarising evidence using network meta-analysis
- Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration
- Test-Retest Variability of Reading Performance Metrics Using MNREAD in Patients with Age-Related Macular Degeneration
- Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration
- Age-Related Macular Degeneration and the Other Double Helix The Cogan Lecture
- A matter of public interest
- Bevacizumab for the treatment of neovascular age related macular degeneration